Goldman Sachs’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
6,148,959
+3,382,715
| +122% | +$7.43M | ﹤0.01% | 3036 |
|
|
2026
Q1 | $6.75M | Buy |
2,766,244
+476,786
| +21% | +$956K | ﹤0.01% | 3409 |
|
|
2025
Q4 | $3.14M | Buy |
2,289,458
+1,085,750
| +90% | +$1.43M | ﹤0.01% | 4188 |
|
|
2025
Q3 | $1.49M | Sell |
1,203,708
-4,299,433
| -78% | -$5.13M | ﹤0.01% | 4729 |
|
|
2025
Q2 | $6.22M | Sell |
5,503,141
-350,833
| -6% | -$466K | ﹤0.01% | 3202 |
|
|
2025
Q1 | $8.55M | Buy |
5,853,974
+3,747,397
| +178% | +$7.06M | ﹤0.01% | 2843 |
|
|
2024
Q4 | $4.49M | Sell |
2,106,577
-56,026
| -3% | -$138K | ﹤0.01% | 3553 |
|
|
2024
Q3 | $6.06M | Buy |
2,162,603
+632,556
| +41% | +$1.69M | ﹤0.01% | 3174 |
|
|
2024
Q2 | $3.57M | Buy |
1,530,047
+235,401
| +18% | +$694K | ﹤0.01% | 3469 |
|
|
2024
Q1 | $5.79M | Sell |
1,294,646
-2,042,568
| -61% | -$8.52M | ﹤0.01% | 2959 |
|
|
2023
Q4 | $10.7M | Buy |
3,337,214
+1,929,258
| +137% | +$5.47M | ﹤0.01% | 2461 |
|
|
2023
Q3 | $4.46M | Sell |
1,407,956
-92,016
| -6% | -$403K | ﹤0.01% | 3088 |
|
|
2023
Q2 | $7.45M | Buy |
1,499,972
+345,447
| +30% | +$1.87M | ﹤0.01% | 2739 |
|
|
2023
Q1 | $5.7M | Sell |
1,154,525
-463,600
| -29% | -$2.97M | ﹤0.01% | 2938 |
|
|
2022
Q4 | $10.2M | Sell |
1,618,125
-781,458
| -33% | -$7.23M | ﹤0.01% | 2573 |
|
|
2022
Q3 | $25.9M | Buy |
2,399,583
+424,626
| +22% | +$5.77M | 0.01% | 1628 |
|
|
2022
Q2 | $22.5M | Sell |
1,974,957
-987,252
| -33% | -$8.76M | 0.01% | 1805 |
|
|
2022
Q1 | $27M | Buy |
2,962,209
+1,138,944
| +62% | +$11.9M | 0.01% | 1805 |
|
|
2021
Q4 | $27.2M | Sell |
1,823,265
-156,447
| -8% | -$2.76M | 0.01% | 1847 |
|
|
2021
Q3 | $50.9M | Buy |
1,979,712
+264,325
| +15% | +$6.28M | 0.01% | 1274 |
|
|
2021
Q2 | $44.7M | Buy |
1,715,387
+434,309
| +34% | +$12.4M | 0.01% | 1359 |
|
|
2021
Q1 | $45.2M | Sell |
1,281,078
-108,588
| -8% | -$3.66M | 0.01% | 1245 |
|
|
2020
Q4 | $35.1M | Buy |
1,389,666
+548,316
| +65% | +$17.9M | 0.01% | 1407 |
|
|
2020
Q3 | $31.7M | Buy |
841,350
+586,883
| +231% | +$22.1M | 0.01% | 1365 |
|
|
2020
Q2 | $10.9M | Buy |
254,467
+67,739
| +36% | +$2.45M | ﹤0.01% | 2200 |
|
|
2020
Q1 | $3.63M | Buy |
186,728
+11,594
| +7% | +$276K | ﹤0.01% | 2883 |
|
|
2019
Q4 | $4.55M | Buy |
175,134
+69,888
| +66% | +$1.92M | ﹤0.01% | 3034 |
|
|
2019
Q3 | $2.87M | Buy |
105,246
+26,474
| +34% | +$754K | ﹤0.01% | 3285 |
|
|
2019
Q2 | $2.12M | Buy |
78,772
+15,561
| +25% | +$434K | ﹤0.01% | 3501 |
|
|
2019
Q1 | $1.83M | Buy |
63,211
+1,924
| +3% | +$55.8K | ﹤0.01% | 3699 |
|
|
2018
Q4 | $1.65M | Buy |
+61,287
| New | +$1.63M | ﹤0.01% | 3651 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
Goldman Sachs's ALLO Position: Q2 2026 in Review
Goldman Sachs increased its Allogene Therapeutics (ALLO) stake by 122% in Q2 2026, buying an estimated $7.43M and bringing the position to 6,148,959 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3036.
Goldman Sachs first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $50.9M in Q3 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Goldman Sachs held 6,148,959 shares of Allogene Therapeutics worth $12.8M as of Q2 2026.
- Goldman Sachs bought 3,382,715 Allogene Therapeutics shares in Q2 2026, an estimated $7.43M.
- Allogene Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3036 holding.
- Goldman Sachs first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Goldman Sachs's Allogene Therapeutics position peaked at $50.9M in Q3 2021.
- 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.